Sodium Hyaluronate
Also known as: Hyaluronic acid sodium salt, Sodium hyaluronidase
This ingredient is classified as unclassified risk (GIRI score: 1.5/10).
Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Sodium hyaluronate is the sodium salt form of hyaluronic acid, identical in bioactivity. Oral intake is well tolerated. Very safe at recommended doses with no meaningful drug interactions documented.
Biological and Chemical Classification
Information not yet available for this ingredient profile.
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Joint Support
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Sodium Hyaluronate indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 14:15
Evidence Distribution
-
Observational / other LOW evidence YELLOWIntra-articular dual-targeted hydrogel co-delivering diacerein nanoparticles and ketorolac for modulating neuroimmune interplay and cartilage degeneration in osteoarthritis. ↗Heikal LA et al.. Intra-articular dual-targeted hydrogel co-delivering diacerein nanoparticles and ketorolac for modulating neuroimmune interplay and cartilage degeneration in osteoarthritis.. Drug Deliv Transl Res. 2026. PMID:41874937.PMID 41874937 ↗Journal Drug Deliv Transl ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41874937/
-
Observational / other LOW evidence YELLOWSafety and Efficacy of Hyaluronic Acid-Based Filler for Neck Wrinkles: A Prospective, Multicenter, Randomized, Parallel-Controlled Non-Inferiority Trial. ↗Jiang M et al.. Safety and Efficacy of Hyaluronic Acid-Based Filler for Neck Wrinkles: A Prospective, Multicenter, Randomized, Parallel-Controlled Non-Inferiority Trial.. Clin Cosmet Investig Dermatol. 2026. PMID:41873431.PMID 41873431 ↗Journal Clin Cosmet Investig DermatolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41873431/
-
Observational / other LOW evidence YELLOWA Hybrid Gel of Hyaluronic Acid and Poly-L-Lactic Acid for Nasolabial Folds by Ligament-targeted Injection. ↗Zhang S et al.. A Hybrid Gel of Hyaluronic Acid and Poly-L-Lactic Acid for Nasolabial Folds by Ligament-targeted Injection.. Plast Reconstr Surg Glob Open. 2026. PMID:41867340.PMID 41867340 ↗Journal Plast Reconstr Surg Glob OpenYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41867340/
-
Observational / other LOW evidence YELLOWSuprachoroidal VIsco-bucKlING versus gas tamponade for the treatment of rhegmatogenous retinal detachment (VIKING): study protocol for a multi-centre, randomised, controlled feasibility study. ↗Saidkasimova S et al.. Suprachoroidal VIsco-bucKlING versus gas tamponade for the treatment of rhegmatogenous retinal detachment (VIKING): study protocol for a multi-centre, randomised, controlled feasibility study.. Pilot Feasibility Stud. 2026. PMID:41845462.PMID 41845462 ↗Journal Pilot Feasibility StudYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41845462/
-
Observational / other LOW evidence YELLOW[Thumbtack needling combined with sodium hyaluronate eye drops for moderate-to-severe dry eye]. ↗An Y et al.. [Thumbtack needling combined with sodium hyaluronate eye drops for moderate-to-severe dry eye].. Zhongguo Zhen Jiu. 2026. PMID:41839595.PMID 41839595 ↗Journal Zhongguo Zhen JiuYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41839595/
-
Observational / other LOW evidence YELLOWConservative Treatments May Show No Significant Differences for Partial-Thickness Rotator Cuff Tears: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. ↗Liu G et al.. Conservative Treatments May Show No Significant Differences for Partial-Thickness Rotator Cuff Tears: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.. Arthroscopy. 2026. PMID:41838489.PMID 41838489 ↗Journal ArthroscopyYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41838489/
-
Observational / other LOW evidence YELLOWConstruction of soluble sufentanil microneedles and their analgesic effects in a mouse model of cancer pain. ↗Zhao A et al.. Construction of soluble sufentanil microneedles and their analgesic effects in a mouse model of cancer pain.. J Mater Chem B. 2026. PMID:41837882.PMID 41837882 ↗Journal J Mater Chem BYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41837882/
-
Observational / other LOW evidence YELLOWBioactive Platinum Nanozymes Accelerate Diabetic Wound Healing via Anti-Inflammation and Macrophage Polarization Modulation. ↗Shi L et al.. Bioactive Platinum Nanozymes Accelerate Diabetic Wound Healing via Anti-Inflammation and Macrophage Polarization Modulation.. Int J Nanomedicine. 2026. PMID:41836724.PMID 41836724 ↗Journal Int J NanomedicineYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41836724/
-
Observational / other LOW evidence YELLOWTacrolimus for Dry Eye Disease: Translational Insights from Animal Models and Clinical Studies into Molecular Pathways and Anti-Inflammatory Mechanisms. ↗Ivraghi MS et al.. Tacrolimus for Dry Eye Disease: Translational Insights from Animal Models and Clinical Studies into Molecular Pathways and Anti-Inflammatory Mechanisms.. Curr Pharm Des. 2026. PMID:41832678.PMID 41832678 ↗Journal Curr Pharm DesYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41832678/
-
Observational / other LOW evidence YELLOWSodium hyaluronate based multifunctional hydrogels delivering SiRNA for sustained silencing of SMAD3: A novel strategy to treat intrauterine adhesions. ↗Chen K et al.. Sodium hyaluronate based multifunctional hydrogels delivering SiRNA for sustained silencing of SMAD3: A novel strategy to treat intrauterine adhesions.. Carbohydr Polym. 2026. PMID:41832026.PMID 41832026 ↗Journal Carbohydr PolymYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41832026/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Sodium Hyaluronate. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Sodium Hyaluronate
A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.